Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients
Table 3
Serological parameters in four MuSK-MG patients pre and post rituximab therapy.
Patients
RTX therapy
Anti-MuSK abs nmol/L
κ-free mg/mL
λ-free mg/mL
κ/λ
CD19+ cell count %
MGFA score
#10
Pre
0.77
4.00
4.60
0.87
9.40
III b
Post 3 weeks
0.83
4.00
4.60
0.87
0.40
III b
Δ%
+7.79
0.00
0.00
0.00
−95.74
#11
Pre
1.32
18.60
11.50
1.62
11.00
III b
Post 4 weeks
1.41
27.60
14.90
1.85
0.10
II b
Δ%
+6.82
+48.39
+29.57
+14.2
−99.09
#12
Pre
1.12
57.10
31.20
1.83
15.00
III b
Post 6 weeks
1.09
49.80
41.10
1.21
1.00
III b
Δ%
−2.68
−12.78
+31.73
−33.88
−93.34
#13
Pre
0.89
32.30
14.70
2.20
4.00
IV b
Post 8 weeks
0.49
13.50
7.50
1.80
0.20
III b
Δ%
−44.94
−58.20
−48.98
−18.18
−95.00
RTX therapy: the pretherapy sample was collected 8–60 months before first infusion. CD19+ cell count: percent over total peripheral blood lymphocytes. Δ% represents the percent variation over the pretherapy sample.
